BOSTON, July 7, 2021 /PRNewswire/ -- Stealth
BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology
company focused on the discovery, development, and
commercialization of novel therapies for diseases involving
mitochondrial dysfunction, today announced that it has joined the
Rare Disease Company Coalition, an alliance of life science
companies committed to discovering, developing, and delivering rare
disease treatments for the patients they collectively serve.
"We are thrilled to be a part of the first-of-its-kind Rare
Disease Company Coalition, which is focused on supporting rare
disease patients through the development of innovative
therapeutics," said Reenie McCarthy,
Chief Executive Officer at Stealth. "We look forward to working
with the other inspiring companies to foster greater understanding
of the unique challenges and circumstances associated with the
development of rare disease treatments."
The Coalition will engage with policy stakeholders to advocate
for impactful drug and healthcare policies and regulations
currently under discussion, including prescription drug pricing, to
highlight the consequences that blanket legislation can have on
continued innovation for rare disease treatments.
About Rare Disease Company Coalition
The Rare Disease
Company Coalition represents life science companies committed to
discovering, developing and delivering rare disease treatments for
the patients we serve. As an education and advocacy-focused
coalition of companies, our goal is to inform policymakers of the
unique challenges and promises of rare disease drug discovery,
development and manufacturing for small population sizes in order
for critical innovation to continue. To achieve this goal, we will
use our unified voice to advocate for long-term, consistent,
equitable and sustainable government policies that enable life
science companies to continue to bring hope and provide access to
approved treatments to people living with rare diseases. For more
information, please visit rarecoalition.com
About Stealth
We are a clinical-stage biotechnology
company focused on the discovery, development, and
commercialization of novel therapies for diseases involving
mitochondrial dysfunction. Mitochondria, found in nearly every cell
in the body, are the body's main source of energy production and
are critical for normal organ function. Dysfunctional mitochondria
characterize a number of rare genetic diseases and are involved in
many common age-related diseases, typically involving organ systems
with high energy demands such as the heart, the eye, and the brain.
We believe our lead product candidate, elamipretide, has the
potential to treat both rare metabolic cardiomyopathies, such as
Barth, Duchenne muscular dystrophy and Friedreich's ataxia, rare
mitochondrial diseases entailing nuclear DNA mutations, as well as
ophthalmic diseases entailing mitochondrial dysfunction, such as
dry age-related macular degeneration and Leber's hereditary optic
neuropathy. We are evaluating our second-generation clinical-stage
candidate, SBT-272, and our new series of small molecules, SBT-550,
for rare neurological disease indications following promising
preclinical data. We have optimized our discovery platform to
identify novel mitochondria-targeted compounds which may be
nominated as therapeutic product candidates or utilized as
mitochondria-targeted vectors to deliver other compounds to
mitochondria.
Investor Relations
Stern Investor Relations
Janhavi Mohite, 212-362-1200
IR@StealthBT.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/stealth-biotherapeutics-joins-the-rare-disease-company-coalition-301327067.html
SOURCE Stealth BioTherapeutics Inc.